Interestingly, SPOA did not reduce the activation and expression of normal c-ABL kinase, and had no cytotoxicity on BCR-ABL negative cells, which partly confirmed the specificity of SPOA targeting CML cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.